Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes

Diabetologia

Volumn 41, Issue 10, 1998, Pages 1127-1132

  Paolisso, G ^a,c   Tagliamonte, M R ^a   Rizzo, M R ^a   Gualdiero, P ^a   Saccomanno, F ^a   Gambardella, A ^a   Giugliano, D ^a   D'Onofrio, F ^a   Howard, B V ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Medlantic Research Institute   (United States)

^c Servizio di Astanteria Medica   (Italy)

Author keywords

Acipimox; Acute insulin response; Free fatty acids; Insulin mediated glucose uptake; Type II diabetes mellitus

Indexed keywords

ACIPIMOX; FATTY ACID; GLUCAGON; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; INTRALIPID; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT SYSTEM; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELATIVE; RESPIRATORY QUOTIENT;

ADULT; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; INSULIN; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PLACEBOS; PYRAZINES;

EID: 0031753344     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051041     Document Type: Article

References (25)

1. Groop LC, Bonadonna RC, Del Prato S, Rathiesz K, Zyck K, Ferrannini E, De Fronzo RA (1989) Glucose and free fatty acids metabolism in non.insulin dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84: 205-213
2. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, De Fronzo RA (1991) The role of free fatty acids metabolism in the pathogenesis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 72: 96-107
3. Paolisso G, Tataranni A, Foley JE, Bogardus C, Howard BV, Ravussin E. (1995) High concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38: 1213-1217
4. Milburn JL, Hirose H, Lee YH et al. (1995) Pancreatic β-cells in obesity: evidence for functional, morphologic and metabolic abnormalities by increased long-chain fatty acids. J Biol Chem 270: 1295-1299
5. Hirose H, Lee YH, Iuman LR, Nagasawa Y, Johnson JH, Unger RH (1996) Defective fatty acid mediated cell compensation in Zucker-diabetic fatty rats. J Biol Chem 271: 5633-5637
6. Crespin SR, Greenough WB, Steinberg D (1973) Stimulation of insulin secretion by long-chain free fatty acids. J Clin Invest 52: 1979-1984
7. Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE (1992) Malonyl-CoA and long-chain acyl-CoA esters as metabolic coupling factor in nutrients-induced insulin secretion. J Biol Chem 267: 5802-5810
8. Zhou YP, Grill V (1994) Long-term exposure of rat pancreatic islet to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93: 870-876
9. Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varricchio M, D'Onofrio F (1995) Opposite effects of short-and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 38: 1295-1299
10. Boden G, Chen X, Rosnar J, Barton M (1995) Effect of a 48 h fat infusion on insulin secretion and glucose utilization. Diabetes 44: 1239-1242
11. Eriksson J, Froussila-Kallunki A, Ekstand A, Saloranta C, Widen E, Schalin C, Groop L (1989) Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med 321: 337-343
12. Warram J, Martin B, Krolewski A, Soelleuer S, Kahn C (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 113: 909-915
13. Pimenta W, Korytkoeski M, Mitrokon A et al. (1995) Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose tolerant individuals with first degree NIDDM relative. JAMA 273: 1855-1861
14. World Health Organization (1985) Diabetes mellitus: Report of WHO study group. World Health Organization, Geneva (Technical Report Series 727: 9-17)
15. Ferrannini E (1990) The theoretical basis of indirect calorimetry: methodological and interpretative problems. Metabolism 258: 339-342
16. Dole VP, Meinertz H (1960) Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 235: 2595-2599
17. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett P (1990) A two step model for the development of non-insulin dependent diabetes. Am J Med 90: 229-235
18. Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44: 863-870
19. Sako Y, Grill V (1990) A 48 h lipid infusion in the rat time-dipendently manner inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127: 1580-1589
20. Capito K, Hansen SE, Healeskov CJ, Thomas PJ (1992) Fat induced changes in mouse pancreatic islets, insulin secretion, insulin biosynthesis and glucose metabolism. Acta Diabetol 28: 193-198
21. Ohneda M, Inman LR, Unger RH (1995) Caloric restriction in obese pre-diabetic rats prevents β-cell depletion, loss of β-cell GLUT2 and glucose incompetence. Diabetologia 38: 173-179
22. Brun T, Jeannet-Assimacopoulos F, Corkey BE, Prentki M (1997) Long-chain fatty acid inhibit acetyl-CoA carboxylase gene expression in the pancreatic β-cell Line INS-1. Diabetes 46: 393-400
23. Perseghin G, Ghosh S, Gerow K, Shulman GI (1997) Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46: 1001-1009
24. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KGMM (1992) Metabolic effects of suppression of non-esterified fatty acids levels with acipimox in obese NIDDM subjects. Diabetes 41: 1400-1408
25. Saloranta C, Taskinen MR, Widen E, Harkonen M, Melander A, Groop L (1993) Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 42: 1559-1566